Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.
A network meta-analysis of 32 randomized trials found that balanced crystalloid solutions were associated with lower mortality, reduced acute kidney injury, and shorter hospital stays in patients with sepsis or septic shock.
A secondary analysis of the EMPACT-MI trial, published in Nature Cardiovascular Research, shows that the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin stabilizes kidney function and reduces heart failure hospitalizations in patients who have recently experienced a heart attack.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Finerenone plus empagliflozin reduced urinary albumin-to-creatinine ratio by 29% to 32% more than either drug alone in patients with chronic kidney disease and type 2 diabetes.
After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.